why choose us

First received: September 27, 2022

Clinical Trial: Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Heart Failure With Preserved Ejection Fraction

Study Type: INTERVENTIONAL


Official Title: SOTA-P-CARDIA Trial: A Randomized Trial of Sotagliflozin in HFpEF Patients Without Diabetes

Brief Summary: The clinical benefits of the dual Sodium-Glucose cotransporter (SGLT) 1 and 2-inhibition have recently been reported in two clinical trials.The SOLOIST reported the benefits of sotagliflozin in Type-2 Diabetes Mellitus (T2DM) patients hospitalized for worsening of Heart Failure (HF), while the SCORED involved T2DM patients with Chronic Kidney Disease (CKD).It is worth noting that not only did the event curves separate within the first week post-treatment, but the effects of sotagliflozin on HF-related outcomes…

Read more